LivaNova PLC (NASDAQ:LIVN) Expected to Post Quarterly Sales of $246.97 Million

Wall Street analysts predict that LivaNova PLC (NASDAQ:LIVN – Get Rating) will post sales of $246.97 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for LivaNova’s earnings, with the highest sales estimate coming in at $249.80 million and the lowest estimate coming in at $245.30 million. LivaNova posted sales of $264.50 million during the same quarter last year, which suggests a negative year over year growth rate of 6.6%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that LivaNova will report full year sales of $1.02 billion for the current year, with estimates ranging from $1.01 billion to $1.02 billion. For the next year, analysts expect that the firm will post sales of $1.09 billion, with estimates ranging from $1.08 billion to $1.11 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow LivaNova.

LivaNova (NASDAQ:LIVN – Get Rating) last announced its quarterly earnings data on Wednesday, May 4th. The company reported $0.48 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.48. LivaNova had a negative net margin of 9.69% and a positive return on equity of 9.57%. The company had revenue of $240.20 million during the quarter, compared to analysts’ expectations of $231.57 million. During the same period in the previous year, the company earned $0.35 EPS. The business’s quarterly revenue was down 3.0% compared to the same quarter last year.

Several research firms have commented on LIVN. Piper Sandler decreased their target price on shares of LivaNova from $104.00 to $99.00 in a research report on Thursday, May 5th. Zacks Investment Research lowered shares of LivaNova from a “hold” rating to a “sell” rating in a research note on Tuesday. UBS Group upgraded shares of LivaNova from a “neutral” rating to a “buy” rating and set a $96.00 price target for the company in a research report on Thursday, February 24th. Wolfe Research initiated coverage on shares of LivaNova in a research note on Tuesday, April 5th. They issued an “outperform” rating and a $95.00 price objective on the stock. Finally, Needham & Company LLC dropped their price target on shares of LivaNova from $120.00 to $106.00 and set a “buy” rating on the stock in a research note on Thursday, February 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, LivaNova presently has an average rating of “Buy” and an average target price of $100.71.

Shares of NASDAQ:LIVN opened at $58.96 on Tuesday. The company has a quick ratio of 0.82, a current ratio of 2.63 and a debt-to-equity ratio of 0.35. LivaNova has a fifty-two week low of $58.60 and a fifty-two week high of $93.89. The firm has a 50-day simple moving average of $78.56 and a 200 day simple moving average of $80.33. The company has a market cap of $3.14 billion, a PE ratio of -29.63 and a beta of 0.91.

In other news, CEO Damien Mcdonald sold 2,784 shares of the company’s stock in a transaction that occurred on Tuesday, March 29th. The shares were sold at an average price of $81.50, for a total value of $226,896.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction on Friday, February 25th. The stock was sold at an average price of $80.00, for a total transaction of $80,000.00. The disclosure for this sale can be found here. Insiders sold 5,784 shares of company stock valued at $470,316 in the last ninety days. Insiders own 0.37% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Column Capital Advisors LLC raised its position in shares of LivaNova by 109.1% in the first quarter. Column Capital Advisors LLC now owns 345 shares of the company’s stock valued at $28,000 after purchasing an additional 180 shares during the period. First Horizon Advisors Inc. raised its position in shares of LivaNova by 892.3% in the third quarter. First Horizon Advisors Inc. now owns 387 shares of the company’s stock valued at $46,000 after purchasing an additional 348 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of LivaNova in the third quarter valued at about $88,000. US Bancorp DE raised its position in shares of LivaNova by 15.3% in the third quarter. US Bancorp DE now owns 1,564 shares of the company’s stock valued at $123,000 after purchasing an additional 208 shares during the period. Finally, O Shaughnessy Asset Management LLC raised its position in shares of LivaNova by 21.2% in the third quarter. O Shaughnessy Asset Management LLC now owns 2,675 shares of the company’s stock valued at $212,000 after purchasing an additional 468 shares during the period. Hedge funds and other institutional investors own 97.34% of the company’s stock.

LivaNova Company Profile (Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Read More